Scan parameters
- Window: 2026-06-04 (1-day floor; most recent prior danbury report was 2026-06-04)
- Passes: (a) conditionQuery PCNSL/PV/TCL/GvHD terms, Phase 2/3, all statuses; (b) tracked molecules × priority sponsors, no condition/phase filter; (c) priority sponsors × same conditions, phases EARLY_PHASE1/PHASE1/PHASE4/NA
- Pass (a): 9 hits; pass (b): 3 hits (2 already in a); pass (c): 2 hits (both already seen). Deduped unique: 10. In-scope candidates: 4.
1. NCT04984837 — Lacutamab in PTCL (TELLOMAK) | ENROLLMENT CLOSED
NCT04984837 · Innate Pharma / The Lymphoma Academic Research Organisation · Phase 2 · n=49
Signal: Enrollment closure — RECRUITING → ACTIVE_NOT_RECRUITING.
Version evidence: v8 (2026-06-02) changed OverallStatus to ACTIVE_NOT_RECRUITING; prior v7 (2026-04-15) was RECRUITING. Modules: Study Status, Study Design, Contacts/Locations. Transition confirmed within window.
Context: TELLOMAK is the pivotal Phase 2 of lacutamab (IPH4102, anti-KIR3DL2 mAb, Innate Pharma) in relapsed/refractory T-cell lymphomas including nodal PTCL and Sézary syndrome. Enrollment closure at n=49 positions a readout within the next 12–18 months (PCD 2028-04-30). KIR3DL2 is selectively expressed on malignant T cells; this remains the only clinical program in this target class. Sanofi has a collaboration with Innate that includes lacutamab — a positive readout would accelerate BLA filing discussions.
2. NCT05996627 — Belumosudil Pre-emptive cGvHD | SITE EXPANSION
NCT05996627 · Fred Hutchinson Cancer Center / Sanofi · Phase 2 · n=82 · RECRUITING
Signal: Site additions — Contacts/Locations module updated.
Version evidence: v14 (2026-06-03) touched Study Status + Contacts/Locations; prior v13 (2026-02-13) touched only Study Status. Status unchanged (RECRUITING both versions). Site additions confirmed within window.
Context: This trial tests belumosudil (ROCK2 inhibitor, Rezurock; Sanofi/Kadmon) as pre-emptive therapy for cGvHD — one step earlier than its approved 3L indication. If positive, it would expand the label into earlier-line cGvHD and widen the addressable market significantly. Active site expansion with PCD 2028-04-30 indicates healthy accrual pace.
3. NCT07357727 — Pelabresib + Ruxolitinib in MF/PPV-MF (Novartis) | SITE EXPANSION
NCT07357727 · Novartis Pharmaceuticals · Phase 3 · n=460 · RECRUITING
Signal: Rapid consecutive site additions.
Version evidence: v9 (2026-06-02) and v10 (2026-06-03) both touched Study Status + Contacts/Locations; OverallStatus RECRUITING in both. Site additions confirmed within window.
Context: Pelabresib (DAK539, BET inhibitor, Novartis) + ruxolitinib in MF including Post-polycythemia Vera MF (PPV-MF). PPV-MF is the natural disease progression endpoint from untreated/undertreated PV; a successful Phase 3 creates competitive pressure on the upstream PV market. Ruxolitinib is a tracked molecule; Novartis is a priority sponsor. Consecutive same-week site expansions signal aggressive global enrollment. Scope hygiene note: Consider adding pelabresib (DAK539) to tracked_molecules under the PV/MPN section.
Pass (b) catch — not promoted
NCT07252050 — Ruxolitinib-enhanced haplo HCT in sickle cell disease (Incyte as collaborator, not lead sponsor; Phase 1/2; SCD is outside scope conditions). Not promoted.
Candidates classified as noise
- NCT06271057 (golcadomide post-CAR-T in systemic DLBCL; academic sponsor): not PCNSL-specific; out of scope.
- NCT03960840 (rapcabtagene autoleucel; Novartis): not a tracked molecule; conditions CLL/ALL/DLBCL not PCNSL-specific; old trial (2019).
- NCT07443137 (CLEAR-1; Stanford/Novartis collaborator; Phase 1 LBCL): not CNS-specific; Novartis is collaborator only.
- Remaining pass (a) hits (NCT07223021, NCT07328503, NCT03919240, NCT05800210): B-ALL or mixed heme malignancy; outside scope.
|